Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea
Links shared publicly online about this topic.
- 591total visits
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea
Vicept Therapeutics, Inc. announced today positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the treatment of Type I Rosacea (Erythematotelangiectatic Rosacea). The results demonstrated a statistically significantrebound" or tachyphylaxis was observed.
View full resource at news-medical.net
Tags: Rosacea, Dairy, Clinical Trial, Relationship
Most Recently Shared on January 10, 2011 at 2:26 pm By:
Vicept reports positive data from V-101 Phase II clinical trial for Type I Rosacea: Vicept Therapeutics, Inc. an... http://bit.ly/fMvanz
Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotelangiectatic Rosacea)
medicalnewstoday.com — “Vicept Therapeutics, Inc. announced positive study results from a Phase II clinical trial evaluating the dose-response relationship of four concentrations of V-101 cream, a topical cream for the t” View full resource at medicalnewstoday.com
Most Recently Shared on January 12, 2011 at 1:05 pm By:
MNT Dermatology News Dermatology and Health News
Vicept Therapeutics Announces Positive Phase II Data Of V-101 For The Treatment Of Type I Rosacea (Erythematotelangiec... http://mnt.to/3PSF
Advertisement
